To the full analysis
Sichuan Kelun Pharmaceutical stock: growth
002422.SZSichuan Kelun Pharmaceutical reported $2.75B in revenue for fiscal 2025, down 15.9% on the prior year, up 2.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.1%
per year from 2007 to 2025, per share 10.3%
Earnings (Annual rate)
12.1%
per year from 2007 to 2025, per share 9.5%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2007 | |
|---|---|---|---|
| Revenue | 2.2% | 9.0% | 13.1% |
| Revenue per share | 0.0% | 7.9% | 10.3% |
| Earnings | 15.5% | 10.2% | 12.1% |
| Earnings per share | 13.0% | 9.0% | 9.5% |
| Free cash flow | 3.8% | no data | no data |
| Free cash flow per share | 1.6% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $302.35M | $32.44M | −$993.52K |
| 2008 | $390.16M | $46.47M | −$825.46K |
| 2009 | $482.93M | $64.16M | −$3.69M |
| 2010 | $603.82M | $99.16M | −$74.67M |
| 2011 | $765.39M | $144.88M | −$249.2M |
| 2012 | $882.58M | $163.09M | −$355.53M |
| 2013 | $1.02B | $161.89M | −$181.23M |
| 2014 | $1.2B | $150.25M | −$230.79M |
| 2015 | $1.16B | $96.77M | −$90.08M |
| 2016 | $1.28B | $87.67M | $53.38M |
| 2017 | $1.71B | $112.25M | −$56.18M |
| 2018 | $2.45B | $181.9M | $243.59M |
| 2019 | $2.64B | $140.64M | $132.82M |
| 2020 | $2.47B | $124.38M | $148.24M |
| 2021 | $2.59B | $165.34M | $278.42M |
| 2022 | $2.86B | $255.74M | $334.64M |
| 2023 | $3.22B | $368.33M | $535.05M |
| 2024 | $3.27B | $440.28M | $422.09M |
| 2025 | $2.75B | $255.23M | $178.47M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Strong
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.